Mandate

Vinge advises EQT in connection with sale of care giant Aleris

July 02, 2010

EQT III has entered into an agreement to sell the Aleris healthcare group to Investor AB. The transaction value is SEK 4.4 billion with a supplementary purchase price of up to SEK 100 million. The transaction is subject to approval by the relevant competition authorities.

The Vinge team advising EQT consisted of Tuula Tallavaara, David Andersson, Johan Mattsson and Ulrich Ziche. Peter Alstergren provided competition law advice and Carl Gustav De Geer was the responsible partner.

Aleris has approximately 5000 employees and has operations in Sweden, Norway and Denmark. Aleris’ turnover in 2009 was approximately SEK 4 billion.

Related

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its rights issue

Vinge has advised Vicore Pharma Holding AB (publ) in connection with an oversubscribed rights issue of shares whereby Vicore receives issue proceeds of approximately SEK 782 million before deduction of transaction costs.
October 22, 2024

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its directed share issue

Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore receives issue proceeds of approximately SEK 100 million before deduction of transaction costs.
October 22, 2024

Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS

Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS. The proceedings, which included considerations regarding state aid approved by the European Commission, have among other things involved restructuring, debt write-downs as well as an investment by a consortium consisting of Castlelake, Air France-KLM, Lind Invest and the Danish state. In total, the investment amounted to approximately USD 1.2 billion in SAS, divided into USD 475 million in unlisted equity and USD 725 million in convertible debt.
October 21, 2024